SAN DIEGO—(BUSINESS WIRE)—Nov. 30, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced the appointment of Srdjan (Serge) Stankovic,M.D., M.S.P.H., as Executive Vice President, Head of Research andDevelopment. With a background in clinical and academic psychiatry, Dr.Stankovic brings over 20 years of executive level experience in drugdevelopment and clinical and medical affairs.
“I am delighted to welcome Serge to our team,” said Steve Davis,ACADIA’s President and Chief Executive Officer. “Serge has a trackrecord of transforming promising research into important medicines thataddress unmet needs of patients. We look forward to his contributions aswe advance NUPLAZID™ through NDA review for Parkinson’s diseasepsychosis, prepare for the planned commercialization of NUPLAZID in theUnited States and continue our efforts to explore the full potential ofNUPLAZID to treat patients suffering from additional CNS disorders.”
“There is a strong need for continued innovation in the treatment of CNSdisorders such as Parkinson’s disease, Alzheimer’s disease, andschizophrenia,” said Dr. Stankovic. “ACADIA is at the forefront indeveloping groundbreaking medicines to treat debilitating symptomsassociated with these diseases. I look forward to leading the team inadvancing the promising development programs with NUPLAZID.”
Dr. Stankovic has built and led multidisciplinary teams for smallmolecules and biologics in therapeutic areas including neurology,psychiatry, oncology, cardiology and pain. He has led teams toachieve approvals of KEPPRA®, FENTORA®, TREANDA®,NUVIGIL® and ARISTADA™.
Dr. Stankovic most recently served as Senior Vice President of ClinicalDevelopment and Medical Affairs at Alkermes plc. from 2013 to 2015.Prior to Alkermes, he held the position of Senior Vice President andHead of Global Clinical Development for Teva Pharmaceuticals Ltd. He wasappointed to this role following Teva’s acquisition of Cephalon, Inc.where he served as Senior Vice President, Worldwide Clinical Research.Dr. Stankovic also held executive positions in research and developmentat Forest Laboratories, Inc., Neurogen Corporation, Johnson and Johnson,and UCB. Dr. Stankovic received his M.D. from the University of Belgradeand holds a Master of Science in Public Health from the University ofAlabama at Birmingham.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application (NDA) in Parkinson’s disease psychosis to the FDAand which has the potential to be the first drug approved in the UnitedStates for this condition. The FDA has classified the NUPLAZID NDA ashaving Priority Review status. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial in schizophrenia. ACADIA also hasclinical-stage programs for glaucoma and, in collaboration withAllergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the potential for NUPLAZID(pimavanserin) to be the first drug approved in the United States forParkinson’s disease psychosis (PDP) and the potential timing of suchapproval, if approved at all, by the FDA; the potential contributions ofDr. Stankovic to ACADIA; the progress, timing and results of ACADIA’sdrug discovery and development programs, either alone or with a partner,including the progress and expected timing of clinical trials; theability of NUPLAZID to treat debilitating symptoms associated withmultiple CNS disorders; the potential of the NUPLAZID developmentprograms; and the benefits to be derived from ACADIA’s productcandidates, including pimavanserin. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization, andcollaborations with others, and the fact that past results of clinicaltrials and past regulatory decisions may not be indicative of futuretrial results or future regulatory decisions, respectively. For adiscussion of these and other factors, please refer to ACADIA’s annualreport on Form 10-K for the year ended December 31, 2014 as well asACADIA’s subsequent filings with the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director ofInvestor Relations
(858) 558-2871